Marshall Wace LLP Buys Shares of 361,229 Savara Inc (NASDAQ:SVRA)

Marshall Wace LLP purchased a new stake in Savara Inc (NASDAQ:SVRA - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 361,229 shares of the company's stock, valued at approximately $1,109,000. Marshall Wace LLP owned about 0.21% of Savara at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its holdings in shares of Savara by 10.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,726,850 shares of the company's stock worth $11,564,000 after purchasing an additional 264,825 shares during the period. Vanguard Group Inc. boosted its stake in Savara by 4.6% during the fourth quarter. Vanguard Group Inc. now owns 8,309,970 shares of the company's stock worth $25,512,000 after buying an additional 365,959 shares during the period. Barclays PLC increased its position in Savara by 217.5% during the third quarter. Barclays PLC now owns 231,005 shares of the company's stock valued at $979,000 after acquiring an additional 158,244 shares during the last quarter. SG Americas Securities LLC raised its stake in shares of Savara by 14.0% in the fourth quarter. SG Americas Securities LLC now owns 51,589 shares of the company's stock valued at $158,000 after acquiring an additional 6,330 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Savara by 23.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 69,490 shares of the company's stock worth $295,000 after acquiring an additional 13,420 shares during the last quarter. 87.93% of the stock is owned by institutional investors.

Savara Trading Up 4.3 %

Shares of Savara stock traded up $0.14 on Friday, hitting $3.40. 706,717 shares of the company traded hands, compared to its average volume of 1,296,987. Savara Inc has a 52 week low of $2.26 and a 52 week high of $5.31. The company has a market cap of $586.95 million, a PE ratio of -7.91 and a beta of 0.52. The stock's 50 day moving average price is $2.82 and its 200-day moving average price is $3.06. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13.

Savara (NASDAQ:SVRA - Get Free Report) last issued its earnings results on Thursday, March 27th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The business had revenue of $0.27 million during the quarter. Equities research analysts predict that Savara Inc will post -0.45 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a "buy" rating and set a $6.00 price target on shares of Savara in a research note on Friday, March 28th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $8.83.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.